Cargando…
Clinical MR imaging in Parkinson’s disease: How useful is the swallow tail sign?
BACKGROUND: With conventional MRI, no Parkinson's disease (PD)‐specific abnormalities can be detected. However, there is a critical need for accompanying neuroimaging markers to guide the diagnosis. With high‐resolution susceptibility‐weighted MRI (SWI) sequences, the imaging of nigrosome‐1 (N1...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8323030/ https://www.ncbi.nlm.nih.gov/pubmed/34032020 http://dx.doi.org/10.1002/brb3.2202 |
_version_ | 1783731166397857792 |
---|---|
author | Prasuhn, Jannik Neumann, Alexander Strautz, Robert Dreischmeier, Shalida Lemmer, Felicitas Hanssen, Henrike Heldmann, Marcus Schramm, Peter Brüggemann, Norbert |
author_facet | Prasuhn, Jannik Neumann, Alexander Strautz, Robert Dreischmeier, Shalida Lemmer, Felicitas Hanssen, Henrike Heldmann, Marcus Schramm, Peter Brüggemann, Norbert |
author_sort | Prasuhn, Jannik |
collection | PubMed |
description | BACKGROUND: With conventional MRI, no Parkinson's disease (PD)‐specific abnormalities can be detected. However, there is a critical need for accompanying neuroimaging markers to guide the diagnosis. With high‐resolution susceptibility‐weighted MRI (SWI) sequences, the imaging of nigrosome‐1 (N1) is possible. The so‐called swallow tail sign (STS) has been proposed as a suitable neuroimaging marker for the diagnosis of PD. OBJECTIVES: To investigate whether the absence of the STS can be applied for distinguishing PD patients from healthy controls (HCs). METHODS: SWI images of 44 PD patients and 50 age‐ and gender‐matched HCs were investigated using a 3T MRI scanner. Two trained neuroradiologists blind‐rated the images and evaluated whether the STS was absent (1) on one side or (2) both sides of the participant's midbrain. RESULTS: Our results confirmed good interrater reliability comparable to previously published studies. However, we did not identify any group differences between PD patients and HCs. Measures of diagnostic values revealed overall poor diagnostic performance. CONCLUSIONS: Even though previously stated, our study does not confirm the potential use of the STS as a supportive neuroimaging marker for PD in a clinical setting. In conclusion, there is a critical need for improvements in N1‐targeted MRI sequences and the development of advanced segmentation algorithms. |
format | Online Article Text |
id | pubmed-8323030 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-83230302021-08-04 Clinical MR imaging in Parkinson’s disease: How useful is the swallow tail sign? Prasuhn, Jannik Neumann, Alexander Strautz, Robert Dreischmeier, Shalida Lemmer, Felicitas Hanssen, Henrike Heldmann, Marcus Schramm, Peter Brüggemann, Norbert Brain Behav Original Research BACKGROUND: With conventional MRI, no Parkinson's disease (PD)‐specific abnormalities can be detected. However, there is a critical need for accompanying neuroimaging markers to guide the diagnosis. With high‐resolution susceptibility‐weighted MRI (SWI) sequences, the imaging of nigrosome‐1 (N1) is possible. The so‐called swallow tail sign (STS) has been proposed as a suitable neuroimaging marker for the diagnosis of PD. OBJECTIVES: To investigate whether the absence of the STS can be applied for distinguishing PD patients from healthy controls (HCs). METHODS: SWI images of 44 PD patients and 50 age‐ and gender‐matched HCs were investigated using a 3T MRI scanner. Two trained neuroradiologists blind‐rated the images and evaluated whether the STS was absent (1) on one side or (2) both sides of the participant's midbrain. RESULTS: Our results confirmed good interrater reliability comparable to previously published studies. However, we did not identify any group differences between PD patients and HCs. Measures of diagnostic values revealed overall poor diagnostic performance. CONCLUSIONS: Even though previously stated, our study does not confirm the potential use of the STS as a supportive neuroimaging marker for PD in a clinical setting. In conclusion, there is a critical need for improvements in N1‐targeted MRI sequences and the development of advanced segmentation algorithms. John Wiley and Sons Inc. 2021-05-24 /pmc/articles/PMC8323030/ /pubmed/34032020 http://dx.doi.org/10.1002/brb3.2202 Text en © 2021 The Authors. Brain and Behavior published by Wiley Periodicals LLC https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Research Prasuhn, Jannik Neumann, Alexander Strautz, Robert Dreischmeier, Shalida Lemmer, Felicitas Hanssen, Henrike Heldmann, Marcus Schramm, Peter Brüggemann, Norbert Clinical MR imaging in Parkinson’s disease: How useful is the swallow tail sign? |
title | Clinical MR imaging in Parkinson’s disease: How useful is the swallow tail sign? |
title_full | Clinical MR imaging in Parkinson’s disease: How useful is the swallow tail sign? |
title_fullStr | Clinical MR imaging in Parkinson’s disease: How useful is the swallow tail sign? |
title_full_unstemmed | Clinical MR imaging in Parkinson’s disease: How useful is the swallow tail sign? |
title_short | Clinical MR imaging in Parkinson’s disease: How useful is the swallow tail sign? |
title_sort | clinical mr imaging in parkinson’s disease: how useful is the swallow tail sign? |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8323030/ https://www.ncbi.nlm.nih.gov/pubmed/34032020 http://dx.doi.org/10.1002/brb3.2202 |
work_keys_str_mv | AT prasuhnjannik clinicalmrimaginginparkinsonsdiseasehowusefulistheswallowtailsign AT neumannalexander clinicalmrimaginginparkinsonsdiseasehowusefulistheswallowtailsign AT strautzrobert clinicalmrimaginginparkinsonsdiseasehowusefulistheswallowtailsign AT dreischmeiershalida clinicalmrimaginginparkinsonsdiseasehowusefulistheswallowtailsign AT lemmerfelicitas clinicalmrimaginginparkinsonsdiseasehowusefulistheswallowtailsign AT hanssenhenrike clinicalmrimaginginparkinsonsdiseasehowusefulistheswallowtailsign AT heldmannmarcus clinicalmrimaginginparkinsonsdiseasehowusefulistheswallowtailsign AT schrammpeter clinicalmrimaginginparkinsonsdiseasehowusefulistheswallowtailsign AT bruggemannnorbert clinicalmrimaginginparkinsonsdiseasehowusefulistheswallowtailsign |